25 Aug 2026
By Ronny Allan
0 Comments
External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms

External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms

Clinical Trials and Research, Patient Advocacy, Treatment, ,
Disclaimer: The information in this section is for education only and does not represent a standard care pathway or service. These treatments are not suitable for everyone, and careful patient selection by an experienced multidisciplinary team is essential. Always discuss your individual situation with your own specialist team.   External Beam Radiation Therapy (EBRT) is an established medical treatment with roots dating back to the late 19th century, but modern EBRT is far more precise, and new technologies now allow safer treatment of tumours that were previously difficult to target. It uses high‑energy beams to damage cancer cells.   The…
Read More
24 Jun 2026
By Ronny Allan
0 Comments
Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey

Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey

Clinical Trials and Research, Patient Advocacy, Treatment, ,
  Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals. The evolution of peptide receptor radionuclide therapy (PRRT) has always been driven by a simple idea: if we can deliver more energy to the tumour while sparing normal tissues, outcomes will improve. For years, the…
Read More
23 Jun 2026
By Ronny Allan
0 Comments
Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET

Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET

Clinical Trials and Research, Patient Advocacy, , , ,
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals. I've been luckier than some. I suspect I was treated earlier despite being diagnosed at stage IV (go figure).  I had 3 surgeries 2010-2012 and since then only treatment with a 28 day somatostatin analogue (Lanreotide)…
Read More
22 Jun 2026
By Ronny Allan
0 Comments
SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs

SYHX2008: A New Self‑Injectable subcutaneous Long‑acting Octreotide on the Horizon for NETs

Clinical Trials and Research, Treatment
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals. A new long‑acting octreotide formulation is emerging that could expand treatment options for people with gastroenteropancreatic neuroendocrine tumours (GEP‑NETs). SYHX2008, developed by CSPC Pharmaceutical Group, is a once‑monthly, pre‑filled, subcutaneous long‑acting octreotide designed for self‑administration. For…
Read More
06 Feb 2026
By Ronny Allan
0 Comments
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311)

Clinical Trials and Research,
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors.  The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. Zanzalintinib (XL092) is an investigational, oral, multi-targeted tyrosine kinase inhibitor (TKI) being developed by Exelixis for various advanced cancers, blocking pathways like VEGFR, MET, and TAM kinases (AXL, MER, TYRO3) involved in tumor growth, spread, and resistance to therapy. Everolimus is already known in NET circles. This study has 25…
Read More
13 Jan 2026
By Ronny Allan
0 Comments
Next Generation Total-Body PET/CT: Challenges and Opportunities

Next Generation Total-Body PET/CT: Challenges and Opportunities

Clinical Trials and Research, Patient Advocacy, , , ,
Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide more detailed imaging and acquire PET images in a single bed position. Indeed, vertex to thigh imaging for oncological indications can be obtained in most of the population with the currently available LAFOV systems. Moreover, Total Body (TB) PET, a subtype of LAFOV, enables imaging the entire patient—from vertex through the toes—with one bed-position for most of the population. This review aims to identify possible challenges and opportunities for PET-centres working with TB and LAFOV…
Read More
05 Jan 2026
By Ronny Allan
0 Comments
Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Clinical Trials and Research, , , , ,
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the news - click here Clinical Trial Document - click here Limited to 21 locations so far (17 USA and 4 Spain) - so far. CRN09682, a first‑in‑class non‑peptide drug conjugate (NDC) developed by Crinetics Pharmaceuticals. The company recently announced that the first patient has been dosed in its Phase 1/2 clinical trial — a significant milestone for a therapy designed to deliver precision‑targeted cytotoxic activity without the use of radiation or standard chemotherapy. What is…
Read More
17 Dec 2025
By Ronny Allan
0 Comments
Another Next Generation PET/CT is coming soon. The Omni 128cm Total Body PET – Small Australian trial at Peter Mac

Another Next Generation PET/CT is coming soon. The Omni 128cm Total Body PET – Small Australian trial at Peter Mac

Clinical Trials and Research, Patient Advocacy, ,
A Global first for NET.  Omni 128cm Total Body PET at the Peter MacCallum Cancer Centre in Melbourne Australia.  According to Professor Michael Hofman, they have been using the camera for a couple weeks and it is exceeding their expectations.  They're running a short trial comparing results against regular PETs.  The great news is that part of the trial will be a prospective sub-trial around dual FDG/ DOTATATE.  In fact I now know that the first patient  in the world to be scanned was a Pancreatic NET and you can watch a great video of this event below. What is…
Read More
16 Nov 2025
By Ronny Allan
0 Comments
MP0712 (212Pb x DLL3), Radio-DARPin – DLL3 Radioligand Therapy Trial for Neuroendocrine Neoplasms

MP0712 (212Pb x DLL3), Radio-DARPin – DLL3 Radioligand Therapy Trial for Neuroendocrine Neoplasms

Clinical Trials and Research, , , , , , , , ,
Update 2nd July 2026. First patients dosed.  Molecular Partners and Orano Med have dosed the first patients in a US Phase 1/2a trial of MP0712, a novel Radio-DARPin drug targeting DLL3, a protein highly expressed in small cell lung cancer and other neuroendocrine tumors. This therapy uses lead-212 to deliver targeted alpha radiation to tumors, aiming to improve treatment precision and reduce side effects. Initial safety and efficacy data are expected later in 2026, with comprehensive results anticipated in 2027. The trial is ongoing at five US sites, with more centers planned to open this year. What is Radioligand Therapy?…
Read More
25 Sep 2025
By Ronny Allan
8 Comments
Immunotherapy and Neuroendocrine Neoplasms

Immunotherapy and Neuroendocrine Neoplasms

Clinical Trials and Research, Treatment, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Updated 24th September 2025. Introduction There's a lot of Immunotherapy stuff out there!  The picture regarding its use in Neuroendocrine Neoplasms is not clear and there is no general roadmap printed.  I first heard of Immunotherapy for NETs following attendance at ENETS 2017 in Barcelona. The presentation that sticks out was one given by Dr Matthew Kulke, a well-known NET Specialist in Boston. My reaction to the presentation was one of 'expectation management' and caution i.e. it's too soon to know if we will get any success and when we will get it. He also hinted that it's more likely…
Read More
09 Aug 2025
By Ronny Allan
0 Comments
NETTER-3 – Clinical Trial: [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NETTER-3 – Clinical Trial: [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Clinical Trials and Research, Patient Advocacy, Treatment, ,
Why is this trial important? The output of NETTER-2, suggested Lutathera for GEP-Grade 2 and 3 NETs could be used as a first line treatment. In some areas this appeared to be controversial.  The data from NETTER-1, which was focused on Grade 1 and 2 (less than ki67 of 10%), did not conclude the same, different aim. However, this appears to be the main aim of NETTER-3, to look at the data in the same way as NETTER-2 but for Grade 1 and 2 with similar criteria used on NETTER-1. You might say NETTER-3 is a follow on from NETTER-1 but…
Read More
16 Jul 2025
By Ronny Allan
0 Comments
Ronny Allan’s Glossary of Terms (Basic Edition)

Ronny Allan’s Glossary of Terms (Basic Edition)

Clinical Trials and Research, Diet and Nutrition, Living with Neuroendocrine Cancer, Patient Advocacy, Ronny Allan's "The Trouble with the NET Series", Spotlight on NENs - Types Series, The NET Effect Series, Treatment, ,
Welcome to my Neuroendocrine Cancer terms and definitions list providing a source of meanings for acronyms and medical terms, all sourced from top cancer/Neuroendocrine Cancer sites.  This version is a simple combination of an intelligent search (e.g. type first character to filter etc) plus a simple long list of all the terms in my repository. But each has a link which will direct you to the definition of the term plus where applicable, links to any of my articles where I have tagged this term (therefore providing added context).Please note I’m constantly working on the repository to clean up all definitions, adding…
Read More
29 Jun 2025
By Ronny Allan
6 Comments
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

Clinical Trials and Research, Treatment, , , , , ,
Latest on NET.  Camurus announces completed enrolment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumours December 14, 2023 at 02:01 am EST Lund, Sweden - 14 December 2023 - Camurus (NASDAQ STO: CAMX) today announces completed enrolment in the randomized, active-controlled Phase 3 SORENTO study evaluating the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with neuroendocrine tumours located in the gastrointestinal tract or pancreas (GEP-NET). "The enrolment of patients in SORENTO has exceeded expectations. Going forward, we will continue to collect data for the primary endpoint assessment of superiority in progression-free survival with CAM2029 compared to…
Read More
27 Jun 2025
By Ronny Allan
0 Comments
DLL3 Expression in Neuroendocrine Neoplasms – an overview

DLL3 Expression in Neuroendocrine Neoplasms – an overview

Clinical Trials and Research, Treatment, , , , , ,
Updated 20th August 2025 Background - Conventional therapeutic targets for neuroendocrine tumours (NETs) include somatostatin receptors (SSTRs), mammalian Target of Rapamycin (mTOR), Vascular Endothelial Growth Factor (VEGF), and tyrosine kinases. These pathways are crucial for tumour growth, survival, and angiogenesis. The most well known is SSTRs given that most NETs express these and allows targeted therapies such as somatostatin analogues (SSA) and peptide receptor radionuclide therapy (PRRT) to be used. Other targeted therapies like everolimus and sunitinib, which inhibit mTOR and tyrosine kinases respectively.  Sunitinib also targets VEGF as does cabozantinib. For neuroendocrine carcinomas (Grade 3 poorly differentiated), targeting has…
Read More
06 Jun 2025
By Ronny Allan
0 Comments
A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours

A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours

Clinical Trials and Research, , , , , , , ,
UPDATE 4th July 2026.  From a presentation at SNMII 2026 "New prospective comparative research suggests that the PET/CT radiopharmaceutical 64Cu-SARTATE may offer significant advantages over 68Ga-DOTATATE for detecting liver foci in patients with known or suspected neuroendocrine tumors (NETs)" click here UPDATE 23rd December 2025. (Originally published Apr 2021).  Phase 3 trial in discussion (clinical trials reference detail to follow) Sydney, Australia 22 December 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce it will be commencing a pivotal Phase III…
Read More
26 Apr 2025
By Ronny Allan
6 Comments
Catch up on Ronny Allan’s Blog

Catch up on Ronny Allan’s Blog

Awareness, Clinical Trials and Research, Diet and Nutrition, Humour, Inspiration, Latest ENETS Guidelines, Living with Neuroendocrine Cancer, Newsletters, Patient Advocacy, Ronny Allan's "The Trouble with the NET Series", Spotlight on NENs - Types Series, Survivorship, The NET Effect Series, Travel with Ronny, Treatment
You guys lead busy lives but the aim of this article is to help you catch up. Below are the most read posts in the last 7 days.  Click on anything that takes your fancy.  Many thanks.  To read any article, just click on the title/picture below Latest from Instagram https://www.instagram.com/neuroendocrine.cancer.ronny/ Select of category of posts you'd like to see Disclaimer I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as…
Read More
13 Mar 2025
By Ronny Allan
4 Comments
Histotripsy – the case for use in UK as Histosonics was awarded early market access

Histotripsy – the case for use in UK as Histosonics was awarded early market access

Clinical Trials and Research, Patient Advocacy, Treatment, , ,
Hot off the press - 10 Mar 2026 Wellington Hospital London is now the first independent hospital in Europe to offer Histotripsy.  Clearly treatment at this hospital will need to be funded by the individual or covered by a private healthcare insurance policy.Click here to read more. Hot off the press - 22 Oct 2025 Cambridge treats first NHS cancer patient  A Cambridge patient has become the first person in Europe to receive cutting-edge histotripsy treatment outside of a clinical trial, after the technology was fast-tracked by the Government - marking a major milestone in NHS cancer care. Addenbrooke’s is…
Read More
17 Feb 2025
By Ronny Allan
7 Comments
The NETest® – can it replace Chromogranin A and more?

The NETest® – can it replace Chromogranin A and more?

A Spotlight on NENs - Testing Series, Clinical Trials and Research, Patient Advocacy, , , , , , , , , ,
See Summary below for a quick updateUpdate 8th Dec 2025.  New York State Department of Health Grants Approval of Wren Laboratories’ NETest® 2.0 for Clinical Use Clinically Validated Performance In validation across 3,042 NET patients and 1,084 controls/other cancers, NETest 2.0 demonstrated: Sensitivity: 93% Specificity: 85% Positive predictive value: 95% Negative predictive value: 82% Overall accuracy: 91% These results support broad clinical utility, including: Accurate detection across all NET grades and stages  Identification of minimal residual disease, recurrence, and progression Monitoring and prediction of therapeutic response, including 177Lu-PRRT Prognostic value for progression-free and overall survival Detection of neuroendocrine differentiation in select epithelial tumors Click…
Read More
13 Feb 2025
By Ronny Allan
0 Comments
Lanreotide and Keytruda – the PLANET study (NCT03043664)

Lanreotide and Keytruda – the PLANET study (NCT03043664)

Clinical Trials and Research, , , , ,
Update 13th February 2025.  In my main coverage of Immunotherapy for Neuroendocrine Neoplasms (NENs), you will see a section where one NET specialists described Neuroendocrine Tumours as an “immunological desert”.  What was meant by is that there’s little evidence immunotherapy is effective in the majority of Neuroendocrine Tumours (NETs).  The output from this trial continues to back that view.  It is important to note the nomenclature of NETs rather than NENs as almost all the immunotherapy drug approvals to date have been for Neuroendocrine Carcinomas (NECs). As the trial abstract conclusion said, "We conclude that immune checkpoint blockade had low…
Read More
29 Jan 2025
By Ronny Allan
4 Comments
Clinical Trial of PRRT ITM11 177Lu-Edotreotide – COMPETE for GEPNETs: Awaiting approval for GEPNETs (COMPETE) expected 2026

Clinical Trial of PRRT ITM11 177Lu-Edotreotide – COMPETE for GEPNETs: Awaiting approval for GEPNETs (COMPETE) expected 2026

Clinical Trials and Research, , , , , , , , , , , , , , ,
Update 4th July 2026. Data from the Phase 3 COMPETE trial - ITM11 [177Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early lines of therapy in patients with advanced, progressive GEP NETs. Bonus info about other trials for NET: 1.  There is also an ITM11 product on trial for more aggressive G2/G3 GEPNETs known as COMPOSE - click here 2.  An ITM11 product trial for Lung and Thymic NETs is running and currently in Phase 3 - known as LEVEL - Click here 3.  A ITM11…
Read More
18 Jan 2025
By Ronny Allan
0 Comments
Ronny Allan – Every picture tells a story

Ronny Allan – Every picture tells a story

Awareness, Clinical Trials and Research, Diet and Nutrition, Humour, Inspiration, Latest ENETS Guidelines, Living with Neuroendocrine Cancer, Newsletters, Patient Advocacy, Ronny Allan's "The Trouble with the NET Series", Spotlight on NENs - Types Series, Survivorship, The NET Effect Series, Travel with Ronny, Treatment, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
I always try to use graphics for a number of pictures, I admit mainly to catch people's attention but also because sometimes a picture on its own tells a story or at least provides a great introduction to one. If the picture catches your eye, clicking on will take you to the text.  This post will auto update as new blogs are published. thanks for reading and sharing! Scroll, point, click, read, share! Disclaimer I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s),…
Read More
26 Nov 2024
By Ronny Allan
0 Comments
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Clinical Trials and Research, , ,
What are cancer vaccines?I remember seeing a comment by a NET Specialist on twitter saying, "We need vaccines".  This was in response to a tweet from another NET Specialist reporting dismal data from an immunotherapy drug for Neuroendocrine Carcinomas. In 2020/2021, the word vaccine has been used a lot, but this specialist was not inferring anti-viral treatment, he was talking about "cancer vaccines", an emerging discipline in science where vaccines act as an immunostimulant to treat cancer.  This prompted me to look around and found this trial which may be of interest to you.  However, before anyone gets too excited,…
Read More
14 Nov 2024
By Ronny Allan
10 Comments
Update – Oncolytic Virus Trials for Neuroendocrine Cancer

Update – Oncolytic Virus Trials for Neuroendocrine Cancer

Clinical Trials and Research, , , ,
Updated 28th May 2025 What exactly are Oncolytic Viruses? Oncolytic Viruses infect and break down cancer cells but not normal cells. Oncolytic viruses can occur naturally or can be made in the laboratory by changing other viruses. Certain oncolytic viruses are being studied in the treatment of cancer. Some scientists say they are another type of immunotherapy whilst others say it's too early to classify them as such. The good news is that Neuroendocrine Cancer seems to figure in this work with two of these viruses apparently working on mice to date. Listed below are two active projects involving NETs,…
Read More
26 Oct 2024
By Ronny Allan
10 Comments
PRRT – The Sequel? Alpha-emitter PRRT for Neuroendocrine Tumours (NET)

PRRT – The Sequel? Alpha-emitter PRRT for Neuroendocrine Tumours (NET)

Clinical Trials and Research, , , , , , , , , , , , , ,
Updated and reviewed June 2026. Alpha‑emitter PRRT is emerging as the next major evolution of peptide receptor radionuclide therapy. Instead of using a beta‑emitting isotope such as 177Lu, these new approaches use alpha‑particle–emitting isotopes like 212Pb or 225Ac. The goal is simple: deliver more powerful DNA‑damaging radiation directly into tumour cells while keeping the impact on surrounding tissues as low as possible. This is still experimental, but the science is compelling — and the early clinical signals are strong enough that alpha‑emitter PRRT is now considered one of the most important areas to watch in NET research. How alpha‑emitter PRRT…
Read More
28 Sep 2024
By Ronny Allan
0 Comments
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)

Clinical Trials and Research, , , ,
One of the common question areas I see in my patient group of 10,000+ members is about the use of somatostatin analogues (SSAs) prior to, during and after treatment with Peptide Receptor Radionuclide Therapy (PRRT). On a similar subject, I also see people asking about stopping SSAs long term regardless of PRRT, particularly if they are NED and stable. People also ask about individual patients who have decided to stop them and how they managed etc.  Clearly these are difficult discussions and anyone reading should be listening to their doctors, not mimicking what they read on patient groups. But they are…
Read More
20 Sep 2024
By Ronny Allan
0 Comments
CABOMETYX® (cabozantinib) for pNET and epNET

CABOMETYX® (cabozantinib) for pNET and epNET

Clinical Trials and Research, Treatment,
6th August 2026 - FDA Tentative Approval for Omcazio: A New Cabozantinib Capsule Formulation Handa Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Omcazio (cabozantinib) capsules, a novel alternate-salt formulation of the well-established tyrosine kinase inhibitor (TKI). Developed under the Section 505(b)(2) regulatory pathway, Omcazio represents a pharmacological evolution of cabozantinib. Unlike current formulations, this capsule is engineered to improve drug absorption and has demonstrated no clinically significant food effect in bioavailability studies. While a tentative approval indicates the product meets all safety, effectiveness, and manufacturing quality standards, the drug is not yet available…
Read More
04 Sep 2024
By Ronny Allan
4 Comments
Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)

Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)

Clinical Trials and Research, Patient Advocacy, Treatment, , , , , ,
Update 4th September 2024.  I have been informed by a third party and trusted source that this upgrade to Lanreotide Ipsen injection device which I published in 2022, will not happen. Apparently, the project announced in 2022 never really got off the ground.  My own guess is that Ipsen's business case expenditure was too much risk given the rise of the generic Lanreotide meds around the same time, i.e. the return of investment (ROI) would not be recouped.I do not understand why Ipsen did not offer a lower price to remain competitive in UK and elsewhere.  It makes me think that…
Read More
31 Aug 2024
By Ronny Allan
0 Comments
CAR-T clinical trials for Neuroendocrine Cancer (plus bonus section on CAR-NK)

CAR-T clinical trials for Neuroendocrine Cancer (plus bonus section on CAR-NK)

Clinical Trials and Research, , ,
Update 24th August 2026 "Chimeric Halts CAR T-cell Trial Enrolment, Shifts Approach" Chimeric Therapeutics has now stopped enrolment and dosing in the Phase 1 trial after side effects were observed at the highest dose level. The company will not continue developing this version of the CAR T-cell therapy but believes CDH17 remains a valid target and plans to pursue a new in vivo approach. So, what happens next?  Chimeric is now advancing a different approach: an in vivo delivery method for a CDH17-directed CAR T-cell therapy. Rather than modifying a patient’s T cells outside the body, as in the current trial,…
Read More
05 Aug 2024
By Ronny Allan
0 Comments
Clinical Trial: 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Clinical Trial: 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Clinical Trials and Research, ,
What is the LUMOD-ID trial? This is a randomized controlled clinical trial evaluating the impact of forward planning dosimetry for Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals), a radiopharmaceutical approved to treat neuroendocrine tumors by the U.S. FDA. The primary outcome measure is to determine objective response rate in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) treated with dosimetrically-determined LUTATHERA administration compared to active control.  This is done at 6 months after treatment completion along with a secondary outcome correlation of hematologic toxicities every 6 months for 5 years.  The remaining secondary outcome measures are after 5 years to…
Read More
01 Aug 2024
By Ronny Allan
2 Comments
Neuroendocrine Cancer: Glossary of Terms

Neuroendocrine Cancer: Glossary of Terms

Awareness, Clinical Trials and Research, Diet and Nutrition, Living with Neuroendocrine Cancer, Patient Advocacy, Survivorship, Treatment, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Welcome to my Neuroendocrine Cancer terms and definitions list providing a source of meanings for acronyms and medical terms, all sourced from top Neuroendocrine Cancer sites. How to use this list: 1. If your term begins with an A, see the list of As etc.  Ditto for B to Z.  Select your term from the list, the definition will show along with any of my blogs where that term is mentioned – this adds context. . 2. Numerical terms are also listed. Please note I’m constantly working on the repository to clean up all definitions, adding and removing links where necessary, and…
Read More
31 Jul 2024
By Ronny Allan
0 Comments
Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors

Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors

Clinical Trials and Research, , , , ,
Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine TumorsUpdated 31st July 2024 to add Phase 1 results and info regarding Phase 2. Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors - What is PRRT?I'm guessing most of my readers know what Peptide Receptor Radiotherapy (PRRT) is.  But for those new to this field, read more hereWhat is Triapine?Triapine is a ribonucleotide reductase (RNR) inhibitor, I.e. it helps repair DNA.  When I research this drug, I can see it is used in numerous examples of clinical trials in an anti-cancer setting alongside radiotherapy and chemotherapy, in many cancers.Triapine in…
Read More
30 Jul 2024
By Ronny Allan
2 Comments
Lanreotide for Lung NETs – SPINET Clinical Trial

Lanreotide for Lung NETs – SPINET Clinical Trial

Clinical Trials and Research, Treatment, , , , , , , , , , ,
Reviewed and updated 30th July 2024.  Phase III trial data update. Update 30th July 2024. This trial had a low particpation repsonse.  Experts cited the main reason was the increasing use of SSAs for Typical and Atypical Lung NETs in clinical practice; as such, patients were reluctant to enroll in this study, with the risk of receiving a placebo, when they could access the active treatment with a prescription. The above is unfortunate but perhaps the wording of some approvals caused confusion about scope. Together with pragmatic compassionate use in cliniclal practice this has perhaps had an adverse affect in…
Read More
02 Jul 2024
By Ronny Allan
1 Comment
Phase 3 CABINET Clinical Trial – Cabozantinib (Cabometyx) for Advanced Neuroendocrine Tumours

Phase 3 CABINET Clinical Trial – Cabozantinib (Cabometyx) for Advanced Neuroendocrine Tumours

Clinical Trials and Research, , , , , , , , , , , , , , , , , , , , , , , , , ,
Please note this drug was approved and is now covered in a new blog - click here Clinical Trial history retained below for reference purposes BREAKING NEWS - 6th August 2024 Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors. Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors – The FDA assigned a Prescription Drug User Fee Act target action date of April 3, 2025 – – Application is based on results from…
Read More
31 May 2024
By Ronny Allan
0 Comments
NHS England’s new Cancer Vaccine Launch Pad

NHS England’s new Cancer Vaccine Launch Pad

Clinical Trials and Research, Patient Advocacy, Treatment,
Update August 2025.  Patients in England with advanced head and neck cancer are being fast-tracked into a ground-breaking mRNA cancer vaccine trial, as the NHS expands its Cancer Vaccine Launch Pad (CVLP) to accelerate access to cutting-edge treatments. Update April 2025.  Melanoma patients in England get fast-track access to cancer vaccineUpdate March 2025. The UK government announced their intention to abolish NHS England and bring it back under the Department for Health and Social Care (DHSC) (i.e. a merger).  The change programme will take up to 2 years.  In the meantime, the blog will be updated with new nomenclature when further information is…
Read More
30 May 2024
By Ronny Allan
0 Comments
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Clinical Trials and Research, , , , ,
What is the objective of this trial? To test a new drug, ADCT-701 (an Antibody-drug conjugate (ADC)), in people with Neuroendocrine Neoplasms (NENs). The eligibility extends to al adults aged 18 and older with NENs. It is listed in the NIH database under clinical trial identify number NCT06041516 (Reference 1 below). What are Antibody-drug conjugates (ADCs)?  Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the ADCs developed so far are for treating cancer, but there is enormous potential for using ADCs to treat other…
Read More
22 Apr 2024
By Ronny Allan
0 Comments
“An odd disposition of tumours” – less common metastases in Small Intestine and Pancreatic NETs

“An odd disposition of tumours” – less common metastases in Small Intestine and Pancreatic NETs

Clinical Trials and Research, Patient Advocacy, , , ,
Every day is a learning day in NET! When I was diagnosed in 2010, my Oncologist sent me for a specialist scan that would help confirm my staging definition and to document anything that might not have shown up on CT.  This was described as an Octreotide Scan (somatostatin receptor scintigraphy) (now mostly replaced by Somatostatin Receptor PET (SSTR PET) e.g. Ga68/Cu64). Lo and behold, the 3 day Octreotide scan lit up some odd places which seemed to be unconnected to my small intestine primary.  I was already stage IV due to the presence of liver metastases and this was…
Read More
10 Apr 2024
By Ronny Allan
1 Comment
Clinical Trials – 212Pb-DOTAMTATE (alpha-emitter) in Subjects With Somatostatin Receptor Positive Neuroendocrine Tumours

Clinical Trials – 212Pb-DOTAMTATE (alpha-emitter) in Subjects With Somatostatin Receptor Positive Neuroendocrine Tumours

Clinical Trials and Research, Treatment, , , , ,
Update 1st July 2026 - Clinical trial expected to resume at the end of 2026 in a Phase 2 follow-on (details tbc). Update 2nd November 2025 - NANETS output. Efficacy, Safety of 212Pb-DOTAMTATE in PRRT-Naïve Patients With GEP-NETs This is a follow on from the 8th October 2025 update below. Commentary by Dr Mary Maluccio from NOLA NETs. The figures looks great and you can read it or listen to her talking. Click here for that. The phase 3 trials will be PRRT naive patients only (i.e. those who have had no previous PRRT (beta or alpha)). Update 8th October…
Read More
29 Jan 2024
By Ronny Allan
4 Comments
Do we need a new model for Carcinoid Crisis in NETs?

Do we need a new model for Carcinoid Crisis in NETs?

Clinical Trials and Research, Treatment, , , , , , , ,
Update February 2026. Before you read this, please note: Why Practice Is Changing Faster Than the Guidelines Modern peri‑operative management for neuroendocrine tumours is evolving rapidly, and several factors explain why clinical practice in some expert centres has moved ahead of formal guidelines: 1. New evidence challenges long‑held assumptions Recent surgical series — most prominently from OHSU Portland USA — show that prophylactic octreotide does not reliably prevent carcinoid crisis and that crises behave more like distributive shock, responding better to vasopressors than to somatostatin analogues. This directly contradicts decades of dogma. 2. Guidelines update slowly by design Bodies such…
Read More
19 Jan 2024
By Ronny Allan
0 Comments
Clinical Trial – Lutathera NETTER-2 Important Update

Clinical Trial – Lutathera NETTER-2 Important Update

Clinical Trials and Research, Treatment, ,
UPDATE - June 5th 2024. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Summary There are currently no standard first-line treatment options for patients with higher grade 2–3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) treatment.MethodsNETTER-2 was an open-label, randomised, parallel-group, superiority, phase 3 trial. We enrolled patients (aged ≥15 years) with newly diagnosed higher grade 2 (Ki67 ≥10% and ≤20%) and grade 3 (Ki67 >20% and ≤55%), somatostatin receptor-positive…
Read More
16 Jan 2024
By Ronny Allan
0 Comments
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (SWOG S2104)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (SWOG S2104)

Clinical Trials and Research,
What is SWOG S2104? A Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine TumorsPancreatic neuroendocrine tumors (pNETS) account for about 1-2% of all the pancreas tumors for which resection is the only curative intent modality, however, despite surgery, many patients will experience recurrence. Tumor size, positive lymph nodes and higher grade are prognostic factors for recurrence. The U.S. Neuroendocrine Tumor Study Group published a predictive score (Zaidi score but also see inclusion criteria) demonstrating that tumors with a score ≥6 had a 33% likelihood of recurrence by 24 months. Furthermore, it is…
Read More
21 Dec 2023
By Ronny Allan
5 Comments
Clinical Trial of Paltusotine, an oral somatostatin analogue for the Treatment of Carcinoid Syndrome

Clinical Trial of Paltusotine, an oral somatostatin analogue for the Treatment of Carcinoid Syndrome

Clinical Trials and Research, , , , , , , , , , , , ,
What is Paltusotine Paltusotine is the first oral, once-daily, selectively targeted somatostatin receptor type 2 (SST2) agonist being developed for the treatment of acromegaly and carcinoid syndrome. The method of operation appears to be similar in that it wants to bind to somatostatin receptor 2 (SST2).  In the meantime, see short video and note that the drug for Acromegaly is more advanced in pipeline terms (now in Phase 3). In terms of the effect on NETs, these tumours typically over express SST2, somatostatin type 2 receptors. Both SST2 and 3 are involved in apoptosis of neuroendocrine tumour cells.” Paltusotine’s high level…
Read More
18 Dec 2023
By Ronny Allan
6 Comments
Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature

Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature

Clinical Trials and Research, Patient Advocacy, , , ,
What is the gut microbiome?   According to Cleveland Clinic, your gut microbiome is a microscopic world within the world of your larger body. The trillions of microorganisms that live there affect each other and their environment in various ways. They also appear to influence many aspects of your overall health, both within your digestive system and outside of it.  If you read their summary here, you can understand some of the implications of this study. However, as the study concluded, midgut NET patients have an altered gut microbiome which could suggest a role in NET development and provide novel targets…
Read More
12 Dec 2023
By Ronny Allan
0 Comments

Novel Therapeutic Target for Pulmonary Neuroendocrine Tumours Uncovered

Clinical Trials and Research
A culture of miniature neuroendocrine tumors. [Talya Dayton, copyright: Hubrecht Institute.] I'll flesh this out in due course, but this is something I'd like to track. Pulmonary NETs don't have as many treatments as Gastroenteropancreatic NETs (GEP NETs). Thanks for reading. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites Talya L. Dayton Nicolas Alcala Laura Moonen Matthieu Foll Lynnette Fernández-Cuesta Hans Clevers Show all authors Show footnotes Open AccessDOI: https://doi.org/10.1016/j.ccell.2023.11.007Quick summary - click here Disclaimer I am not a doctor or any form of medical professional, practitioner or counsellor. None of…
Read More
02 Dec 2023
By Ronny Allan
2 Comments
Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors – PRRT vs Everolimus

Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors – PRRT vs Everolimus

Clinical Trials and Research, , , , , , , , , ,
US Trial I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177 dotatate) vs the efficacy of Everolimus (Afinitor).  The latter is approved for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease (US FDA wording, Europe is similar). What is this trial? This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in…
Read More
14 Oct 2023
By Ronny Allan
5 Comments
Meet Edison® Histotripsy System – powerful bubbles

Meet Edison® Histotripsy System – powerful bubbles

Clinical Trials and Research, Patient Advocacy, Treatment, , ,
Please read this before asking questions Histotripsy is a new treatment, but it's an ablative technique rather than a drug.  It can be equated to liver embolization or conventional tumour ablation but uses what would appear to be a more effective targeted therapy.  It's early days, the fact that it has been approved by FDA (see wording below) is about all we know but this blog will be kept live. I get asked a lot of questions but some of the detail NET patients tend to ask is simply not available to me.   1. Where can I get this treatment? …
Read More
02 Oct 2023
By Ronny Allan
5 Comments
Neuroendocrine Cancer Clinical Trial – Lutetium-177Lu (Satoreotide)

Neuroendocrine Cancer Clinical Trial – Lutetium-177Lu (Satoreotide)

Clinical Trials and Research, , , , , , ,
What is Satoreotide? It's an agonist treatment. i.e. a 'next generation' radioligand for Peptide receptor radionuclide therapy (PRRT) or more specifically the radiopharmaceutical that binds to both activated and inactivated somatostatin receptors which are upregulated on these tumours. There is far higher binding via this mechanism than standard octreotate. The technical name of the radiopharmaceutical is Satoreotide tetraxetan lutetium-177 (author's note, I'm guessing but it could be a variant of Lanreotide). Somatostatin type 2 (SST2) receptor is overexpressed in many around 80% of NETs, some NEC and in certain hard-to-treat cancers such as small cell lung cancer (SCLC) and neuroblastoma,…
Read More
28 Sep 2023
By Ronny Allan
0 Comments
First and only FDA-cleared, fully automated chromogranin A assay

First and only FDA-cleared, fully automated chromogranin A assay

A Spotlight on NENs - Testing Series, Clinical Trials and Research, Patient Advocacy,
There has been controversy about the utility of Chromogranin A for many years now.  Specialists have been critical about its use but to be fair even those less critical still confirm that alone it would not be trusted to formally diagnose Neuroendocrine Cancer.  That said, it was still controversial when certain US guidelines were updated to recommend it is not regularly tested.  It's well known for being a sensitive but non-specific marker for most tumours of Neuroendocrine type, the non-specificity is mostly due to the other conditions, some of which are highly prevalent in many countries, including but not limited to…
Read More
12 Aug 2023
By Ronny Allan
2 Comments
Lung cancer diagnosed early because of new tool

Lung cancer diagnosed early because of new tool

Clinical Trials and Research, Patient Advocacy, , , ,
I'm a believer in science overtaking mortality figures and there is evidence of that already happening when you read the latest survival figures. But too many are still succumbing to this killer disease.  I also believe that artificial intelligence (AI) has the potential to help. Even with cancers of the lung, where known causes are heavily linked to death rates, are decreasing but that is mainly due to preventative measures such as stopping smoking.  However, not all cancers of the lung are caused by smoking. Most low-grade Lung NETs is a good example, there are others. I've had a flurry…
Read More
05 Aug 2023
By Ronny Allan
2 Comments
The Cancer Legacy of Steve Jobs?

The Cancer Legacy of Steve Jobs?

Awareness, Clinical Trials and Research, , ,
Update June 2026.  HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new financing round with participation from Reed Jobs and Yosemite, whose aim is to “make cancer non-lethal in our lifetime,” alongside several new strategic investors.  Read more click hereClick here to read more about Histotripsy.Update February 2026. Today, Yosemite said that it had raised more than $200 million for a second fund that has a total targeted size of $350 million, with heavy-hitter investors that include biotech giant Amgen, Memorial Sloan Kettering, MIT and venture capitalist John Doerr. Powell…
Read More
02 Aug 2023
By Ronny Allan
0 Comments
Phase 1 Clinical Trial AOH1996 for the Treatment of Refractory Solid Tumors

Phase 1 Clinical Trial AOH1996 for the Treatment of Refractory Solid Tumors

Clinical Trials and Research, , ,
The City of Hope-developed small molecule AOH1996 targets a cancerous variant of the protein PCNA. In its mutated form, PCNA is critical in DNA replication and repair of all expanding tumors. Here we see untreated cancer cells (left) and cancer cells treated with AOH1996 (right) undergoing programmed cell death (violet). (Photo credit: City of Hope) This particular clinical trial for solid tumours has been widely reported in the news this week (July/august 2023). It is touted as a "cancer-killing pill" has appeared to "annihilate" solid tumours in early research - leaving healthy cells unaffected.  Whether these are the words of…
Read More